Serum Protein Electrophoresis: Key Clinical Points
Overview and Technique
Serum protein electrophoresis (SPEP) is an inexpensive, readily available screening tool that separates proteins based on physical properties into distinct fractions: albumin, alpha-1, alpha-2, beta, and gamma globulins 1. This test identifies morphologic patterns in response to inflammation, malignancy, liver/renal failure, and hereditary protein disorders 2.
Major Protein Fractions and Clinical Significance
Albumin
- Normally the largest fraction
- Decreased in: malnutrition, liver disease, nephrotic syndrome, inflammation
- Increased in: dehydration
Alpha-1 Globulin
- Contains alpha-1 antitrypsin, acute phase reactants
- Elevated in acute inflammation
Alpha-2 Globulin
- Contains haptoglobin, ceruloplasmin
- Elevated in acute inflammation, nephrotic syndrome
Beta Globulin
- Contains transferrin, complement components
- May show beta-gamma bridging in cirrhosis
Gamma Globulin
- Contains immunoglobulins (IgG, IgA, IgM)
- Critical for identifying monoclonal and polyclonal gammopathies
Critical Pattern Recognition
Monoclonal Gammopathy (M-spike)
A homogeneous spike-like peak in the gamma region indicates a monoclonal gammopathy and requires immediate further workup 1. This pattern is associated with:
- Multiple myeloma
- Waldenstrom's macroglobulinemia
- Monoclonal gammopathy of undetermined significance (MGUS)
- Smoldering multiple myeloma
- AL amyloidosis
- Plasma cell leukemia
Polyclonal Gammopathy (Broad-based elevation)
A diffuse elevation of gamma globulins indicates polyclonal gammopathy, caused by any reactive or inflammatory process 1.
Workup Algorithm for Monoclonal Gammopathy
Initial Detection
When SPEP shows an M-spike, repeat testing at 3-6 months is mandatory to exclude multiple myeloma or Waldenstrom's macroglobulinemia, as the monoclonal protein is usually recognized by chance 3.
Perform immediately:
- Complete blood count with differential
- Serum calcium and creatinine
- Serum protein electrophoresis with immunofixation
- Free light chain (FLC) assay
- Urine protein electrophoresis with immunofixation if proteinuria present
Risk Stratification for MGUS
Low-Risk MGUS (all three criteria):
- M-protein <15 g/L
- IgG type
- Normal FLC ratio
Management: Follow with SPEP at 6 months, then every 2-3 years if stable 3. Bone marrow examination and skeletal imaging are NOT routinely indicated 3.
Intermediate/High-Risk MGUS (any of):
- M-protein ≥15 g/L
- IgA or IgM type
- Abnormal FLC ratio
Management:
- Bone marrow aspirate and biopsy required at baseline 3
- For IgM: CT scan of chest, abdomen, pelvis (to detect retroperitoneal lymph nodes) 3
- For non-IgM with M-protein >15 g/L or >10 g/L for IgA: consider skeletal survey 4
- Follow with SPEP at 6 months, then annually for life 3
Progression Risk
- MGUS: ~1% per year progression to malignancy 3
- Smoldering myeloma: 10% per year for first 5 years, 3% per year for next 5 years, then 1-2% per year 3
Screening for Hypogammaglobulinemia
Calculated globulin (CG = total protein - albumin) and gamma globulin fraction from SPEP are reliable screening tools for antibody deficiencies 5.
Cutoff Values for Adults:
- CG <22-24 g/L: sensitivity 80-86%, specificity 87-92% 6, 5
- Gamma globulin <7.15-8.9 g/L: sensitivity 96-100%, specificity 88-97% 6, 5
Common pitfall: SPEP is often overlooked in patients with recurrent infections or chronic diarrhea, leading to delayed diagnosis of common variable immunodeficiency (CVID) 7. Consider SPEP in patients with recurrent respiratory infections, chronic diarrhea, or autoimmune disorders.
Key Clinical Caveats
- IgA M-proteins have higher risk: 20.5% probability of ≥10% plasma cell infiltration vs 4.7% for IgG when M-protein ≤15 g/L 4
- Always require bone marrow examination for: unexplained anemia, renal insufficiency, hypercalcemia, bone lesions, or suspicion of AL amyloidosis, regardless of M-protein level 3
- Limited life expectancy: Bone marrow and imaging may be omitted in elderly patients with significant comorbidities 4
- Treatment is not indicated for MGUS or smoldering myeloma outside clinical trials 3